Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables
Modern Rheumatology, 10/05/09

Aramakie T et al. – Good outcome in RA patients treated with tacrolimus can be predictive by some baseline variables. That is clinically valuable for daily practice in the choice of disease-modifying antirheumatic drugs (DMARDs), especially tacrolimus.

Methods

106 RA patients treated with tacrolimus for 6 months entered in study
Association of gender, DAS28-CRP at baseline, concomitant use of methotrexate (MTX), and concomitant use of prednisolone with the achievement of DAS28-CRP remission at 6 months by logistic regression analysis examined

Results

23 of 106 patients (21.7%) achieved DAS28-CRP remission at 6 mos
Concomitant use of MTX by 20 patients (18.9%), prednisolone by 93 (87.7%), and prednisolone > 5 mg/day by 43 (40.6%) at baseline
Logistic regression analysis showed male gender (first) and moderate disease activity at baseline (second) are independent predictors toward achieving DAS28-CRP remission at 6 mos
Maximum tacrolimus dosage administrated for patients over 6-month period appeared not to be predictive for DAS28-CRP remission at 6 mos

<< Previous
Safety Nets Get Stimulus I.T. Funds

Next >>
Reactivation of hepatitis B viral infection in inactive HBSAg...